Detalhe da pesquisa
1.
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence.
Ann Intern Med;
176(9): 1251-1256, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37603868
2.
Federal Enforcement of Pharmaceutical Fraud under the False Claims Act, 2006-2022.
J Health Polit Policy Law;
49(2): 249-268, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37801012
3.
Eroding Judicial Deference to the FDA - Consequences for Public Health.
N Engl J Med;
388(11): 963-966, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36912543
4.
Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Milbank Q;
99(4): 1162-1197, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34375015
5.
Spending on Targeted Therapies for Duchenne Muscular Dystrophy.
JAMA;
331(13): 1151-1153, 2024 04 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38466271
6.
Protecting Medicare's Discretion to Say No to Unproven Therapies.
JAMA;
330(12): 1133-1134, 2023 09 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37682556
7.
Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept.
J Manag Care Spec Pharm;
30(3): 226-233, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088900
8.
Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S.
J Law Med Ethics;
51(2): 448-449, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37655568
9.
Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit.
J Manag Care Spec Pharm;
28(3): 354-361, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35199580
10.
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.
Chest;
162(2): 433-435, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35940656